Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
Other backed projets
Running Care is the first health application dedicated to runners, designed 100% by sports doctors.
PlayTreks, ALL IN ONE app for the music industryMeet the growing demand for transparency in the musi...
VitriCell is a company aiming at providing solutions for safe and efficient cryopreservation of most...
Grainz is cloud based AI for the hospitality sector, designed to optimise margins & maximise eff...
ALX Systems is a Liege-based company that offers embedded artificial intelligence programs on drones...
Originally producer of cold-pressed juice, the young startup Good Move had to reinvent itself in Mar...
Iliium is a blockchain and crypto-currency company focused on creating an easy-to-use and user-frien...
be+SPORTS is a young Belgian company specialized in the development of digital solutions for sports...
CheckHub is a SaaS plugin solution that automates administrative tasks related to people document ma...
Phasya offers software for monitoring the physiological and cognitive states (e.g. drowsiness, stres...